In his goal to deliver good patient outcomes in the treatment of atrial fibrillation (AF), Dr. Sanjiv Narayan led the development of an innovative therapy known as Focal Impulse and Rotor Modulation (FIRM). Dr. Sanjiv Narayan also founded a start-up company that was eventually bought by Abbott Laboratories. The company, Topera, Inc., enabled Abbott to enter the field of treating individuals with AF.
Topera created a rotor identification system using mapping software and an innovative diagnostic catheter. This system assists physicians in finding and targeting the definitive locations of an individual’s heart that are causing atrial fibrillation. An independent study has shown that the system with catheter ablation results in better long-term outcomes and requires fewer procedures than other methods of treatment.
In an ablation procedure, a catheter is positioned in a targeted area of the heart. Energy is then used to disturb the unusual electrical activity in that area associated with AF.
AF is the most prevalent cardiac arrhythmia (abnormal heart rhythm). Around 2.7 million to 6.1 million adult Americans are estimated to have AF. Individuals having this condition are three times more likely to experience heart failure.